Market Cap 35.58M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 65,800
Avg Vol 315,476
Day's Range N/A - N/A
Shares Out 8.70M
Stochastic %K 59%
Beta 1.10
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
Latest News on BCTX
No data available.